Overview

Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.
Phase:
Phase 1
Details
Lead Sponsor:
Vivek Jain
Collaborator:
George Washington University
Treatments:
Oxytocin